4 completed, 3 unknown, 2 active not recruiting. 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Unknown 3 |
| Phase 1 | 6 | Unknown 3, Active not recruiting 2, Completed 1 |
Follow B-Cell Prolymphocytic Leukemia: new trials by email Literature Review of B-Cell Prolymphocytic Leukemia trials Research Report on B-Cell Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2020-09-15 | 2025-02-28 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation - B-Cell Prolymphocytic Leukemia, Hypodiploidy | Phase 2 | Completed | Fred Hutchinson Cancer Center | 16 | 2010-03-18 | 2019-06-11 |
| Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Cyclosporine, Fludarabine Phosphate, Hematopoietic Cell Transplantation - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2003-03-01 | 2017-12-08 |
Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Prolymphocytic, B-Cell (9) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (6) · Lymphoma, Large B-Cell, Diffuse (5) · Leukemia, Prolymphocytic, T-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Hairy Cell (2) · Lymphoma, Non-Hodgkin (2) · Anemia (1) · Burkitt Lymphoma (1) · Chromosome 17 deletion (1) · Hodgkin Disease (1) · Leukemia, Plasma Cell (1)
Chronic Disease (9) · Disease Attributes (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Leukemia (9) · Leukemia, B-Cell (9) · Leukemia, Lymphoid (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9)
Antigens, CD19 (3) · Sensitivity and Specificity (3) · fludarabine phosphate (3) · Cyclophosphamide (2) · Etoposide (2) · Immunotherapy, Adoptive (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Bendamustine Hydrochloride (1) · Carmustine (1) · Cyclosporine (1) · Cyclosporins (1) · Cytarabine (1) · Hematopoietic Stem Cell Transplantation (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Alexey Danilov, MD (1) · Ohio State University Comprehensive Cancer Center (1)
United States (6) · China (3) · Italy (1)
Alexey Danilov (1) · Craig Okada, M.D. (1) · David Maloney (1) · John C Reneau, MD (1) · Lin Yang, Ph.D. (1) · Mohamed Sorror (1) · Tanya Siddiqi (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1)
PMID 28054442, PMID 32499241, PMID 34196037, PMID 34492703, PMID 34515338, PMID 36631449
P30CA015704 (2), P30CA033572 (1), P30CA069533 (1)